Teva to advance vitiligo antibody TEV-'408 into Phase 2b trials
Go back to Teva to advance vitiligo antibody TEV-'408 into Phase 2b trials| TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) | Delayed: 36.44 +0.08 (0.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $36.36 | 52 Week High | $66.55 | |||
| Open | $35.89 | 52 Week Low | $37.82 | |||
| Day High | $36.53 | P/E | N/A | |||
| Day Low | $35.42 | EPS | $0.00 | |||
| Volume | 1,237,420 | |||||
